Outcome of the meeting of Board of Directors of Novartis India Limited (''the Company'') held today i.e. Friday, March 27, 2026 inter-alia to approve the appointment of Ms. Gowree Gokhale ....
NOVARTIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Novartis India's board met on March 27, 2026 and approved two main changes to its independent director lineup. Ms. Gowree Gokhale (DIN: 09351661), a senior solicitor with over 30 years of legal experience in pharma, IP, and data protection, has been appointed as an Additional Non-Executive Independent Director for a five-year term starting April 1, 2026, subject to shareholder approval via postal ballot. At the same time, Ms. Sandra Martyres will complete her second and final term as Independent Director and step down from the board at the close of business on April 18, 2026. The board placed on record its appreciation for Ms. Martyres's contributions. The appointment and cessation are routine governance actions with no management or promoter-level changes.
This is a routine independent director rotation with no impact on operations, financials, or shareholding. Shareholders will get to vote on Ms. Gokhale's appointment through a postal ballot; her legal and pharma regulatory expertise could add value to board oversight, but the stock is unlikely to react materially.